Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0022104 (irritable bowel syndrome)
 8,033 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The effect of domperidone, a peripheral antidopaminergic drug, on sigmoid motor activity in the irritable bowel syndrome, has been evaluated by measuring pressures in 3 opentipped tubes perfused with distilled water at a constant flow rate of 0.636 ml/min and inserted into the sigmoid colon. Domperidone 20 mg i.v. in 10 patients, did not induce any significant change in basal motility, but prevented the increase in motor activity produced by the infusion of dopamine 5 micrograms/kg/min for 10 min. It appears that domperidone had no effect on sigmoid motor activity, although the inhibition of dopamine-induced motility confirms the presence of specific dopaminergic receptors in the colon and the antidopaminergic action of domperidone.
 ...
PMID:Effect of domperidone and dopamine on colonic motor activity in patients with the irritable bowel syndrome. 407 26

Domperidone treatment did not differ significantly from placebo treatment in irritable bowel syndrome patients concurrently put on high fibre diet. No side effects attributable to the drug were encountered. This study further reinforces the necessity to have patients concurrently on a high fibre diet when testing for drug efficiency in the irritable bowel syndrome. Double-blind drug versus placebo studies should be undertaken in the irritable bowel syndrome patients who fail to respond to a high fibre diet. Dopamine receptor sites are unlikely to be primarily involved in the irritable bowel syndrome.
 ...
PMID:Domperidone treatment in the irritable bowel syndrome. 628 74

An evaluation was carried out of the effect of domperidone on gastro-intestinal symptoms in patients with irritable bowel syndrome. Ninety-eight patients were included; 32 in an open pilot study and 66 in a double-blind placebo-controlled study. Domperidone was taken at a dosage of 10 mg tablets 4-times daily. At the end of the 4-week treatment, symptoms had disappeared or were at least markedly improved in about 80% of the domperidone-treated patients. Significant superiority of domperidone to the placebo was observed for the symptom clusters 'post-prandial flatulence', 'abdominal pain' and 'abnormal bowel habit'. No side-effects were reported.
 ...
PMID:Use of the peripheral dopamine antagonist, domperidone, in the management of gastro-intestinal symptoms in patients with irritable bowel syndrome. 699 28